TOMEGLOVIR

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H27N3O4S
Molecular Weight	441.543
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NC3=CC=C(NC(=O)C(C)(C)CO)C=C3

InChI

InChIKey=OSQAKHSYTKBSPB-UHFFFAOYSA-N

InChI=1S/C23H27N3O4S/c1-23(2,15-27)22(28)24-16-11-13-17(14-12-16)25-31(29,30)21-10-6-7-18-19(21)8-5-9-20(18)26(3)4/h5-14,25,27H,15H2,1-4H3,(H,24,28)

HIDE SMILES / InChI

Molecular Formula	C23H27N3O4S
Molecular Weight	441.543
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15652969 | https://www.ncbi.nlm.nih.gov/pubmed/12323400 | https://adisinsight.springer.com/drugs/800012718

Tomeglovir (BAY 38-4766) is a human cytomegalovirus (CMV) terminase complex inhibitor. Treatment with BAY 38-4766 reduced both viremia and DNAemia, as determined by a real-time PCR assay, following guinea pig cytomegalovirus (GPCMV) infection of cyclophosphamide-immunosuppressed strain 2 guinea pigs. BAY 38-4766 also reduced mortality following lethal GPCMV challenge in immunosuppressed Hartley guinea pigs. a combination of BAY 38-4766 with anti-cytomegalovirus drug ganciclovir showed antagonism. Interaction of viral DNA processing inhibitor 2-bromo-5,6-dichloro-1beta-D-ribofuranosyl benzimidazole (BDCRB) with BAY 38-4766 showed a mixed pattern of synergy and antagonism. Tomeglovir had been in phase II clinical trials by Bayer for the treatment of CMV infection. However, this development was discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
CHEMBL3991482: DNA terminase, Human cytomegalovirus 1 Target ID: CHEMBL3991482: DNA terminase, Human cytomegalovirus Sources: https://adisinsight.springer.com/drugs/800012718\|https://www.ncbi.nlm.nih.gov/pubmed/11428244\|https://www.ncbi.nlm.nih.gov/pubmed/28827420	Inhibitor 8297		0.34 µM [IC50]

PubMed

Title	Date	PubMed
Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action.	2001 Dec	11733458
Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo.	2001 Mar	11428244
Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.	2001 Oct	11557492
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.	2001 Oct	11533171
Focus on new drugs in development against human cytomegalovirus.	2002	12215056
Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus.	2002 Oct	12323400
[Drugs against human cytomegalovirus].	2002 Sep	12474580
Antiviral therapies.	2004 Apr	15062765
The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs.	2005 Jan	15652969

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:38:41 GMT 2023` Edited by `admin` on `Fri Dec 15 18:38:41 GMT 2023`
Record UNII	0YPQ44B589
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOMEGLOVIR

Official Name

English

tomeglovir [INN]

Common Name

English

BAY-384766

Code

English

BAY-38-4766

Code

English

Tomeglovir [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C281